What Are Genomic Biomarkers in Cancer Therapy?
Genomic biomarkers in cancer therapy are DNA or RNA alterations—EGFR, BRAF, BRCA, HER2, MSI-H, TMB—that predict response to targeted or immunotherapy when validated for a specific tumor type. NGS panels find actionable alterations in roughly one-third of advanced tumors, but each marker is drug-specific. Motif maps published genomic biomarker associations with PMIDs before teams design profiling protocols or enrichment trials.
TL;DR: Genomic Biomarkers in Oncology
- Same histology can hide different drivers; profiling informs therapy when evidence is indication-specific (Hoadley et al., 2014)
- Predictive pairs are drug-specific: EGFR-TKIs (Mok et al., 2009; Soria et al., 2018), BRAF inhibitors (Chapman et al., 2011), PARP inhibitors in BRCA-mutant breast cancer (Robson et al., 2017)
- MSK-IMPACT found actionable alterations in 36.7% of 10,336 tumors; yield depends on panel, histology, and available therapies (Zehir et al., 2017)
- TMB associates with ICI survival but cutpoints vary by cancer type (Samstein et al., 2019)
- Resistance is heterogeneous; serial genotyping matters (Leonetti et al., 2019)
- Motif maps alteration-drug PMIDs before tumor boards or trial criteria lock
From the Motif team: Last reviewed June 2026. Genomic biomarker literature is indication- and drug-specific. Motif extracts biomarker-treatment associations from PubMed, PMC, and Europe PMC with GRADE-adapted scoring and cross-reference to curated databases. We do not run sequencing or recommend therapy.
Genomic biomarkers are DNA or RNA alterations that inform cancer diagnosis, prognosis, or therapy selection when validated for a specific drug and clinical context. Hoadley et al. (2014) showed that cancers of the same organ separate into molecular subtypes with distinct biology.1 The clinical question is never "should we do genomics?" but "which alteration-drug pairing has trial evidence in this line of therapy?"
FDA-NIH BEST defines predictive biomarkers as those that identify individuals more likely to benefit from a specific treatment (FDA-NIH, 2016).2 A prognostic mutation associated with poor outcome is not automatically a companion diagnostic without treatment interaction evidence (Simon, 2013).3
Predictive Biomarkers With Pivotal Trial Evidence
EGFR-mutant NSCLC. Mok et al. (2009) randomized EGFR-mutation-positive patients to gefitinib or chemotherapy. Progression-free survival favored gefitinib in mutation-positive disease (HR 0.48; 95% CI 0.36 to 0.64).4 Soria et al. (2018) showed first-line osimertinib improved PFS versus gefitinib/erlotinib (median 18.9 vs 10.2 months; HR 0.46).5 Ramalingam et al. (2020) reported median overall survival 38.6 vs 31.8 months.6 These results bind to EGFR sensitizing mutations and TKI generation, not to every lung adenocarcinoma.
BRAF V600E melanoma. Chapman et al. (2011) compared vemurafenib with dacarbazine in previously untreated metastatic melanoma with BRAF V600E. Confirmed response rates were 48% versus 5%.7 Cutaneous squamous-cell proliferations are a known class toxicity and should be monitored.
Germline BRCA and PARP inhibition. Robson et al. (2017) randomized HER2-negative metastatic breast cancer patients with germline BRCA mutations to olaparib or physician's-choice chemotherapy. Median PFS was 7.0 versus 4.2 months (HR 0.58).8 PARP benefit is tied to homologous recombination deficiency biology, not BRCA status alone in every tumor type.
HER2-positive breast cancer. Slamon et al. (2001) established trastuzumab plus chemotherapy benefit in HER2-positive metastatic disease.9 Modern HER2-directed combinations have their own trial programs; literature review must stay drug- and line-specific.
MSI-H / dMMR and checkpoint blockade. Marabelle et al. (2022) reported pembrolizumab in KEYNOTE-158 cohort K (non-colorectal MSI-H/dMMR tumors): objective response rate 30.8% (95% CI 25.8% to 36.2%).10 MSI is a predictive biomarker in defined immunotherapy settings, not a universal immunotherapy switch.
Homologous recombination deficiency (HRD). Litton et al. (2018) randomized newly diagnosed BRCA-mutant advanced ovarian cancer to olaparib or placebo after platinum response (SOLO-1). Progression-free survival at 3 years was 60.4% versus 26.9% (HR 0.30).11 HRD biology extends beyond germline BRCA1/2 to somatic BRCA alterations and genomic scar signatures, but PARP benefit remains drug- and indication-specific. Tumor HRD scores from myChoice, HRDetect, and other algorithms are not interchangeable without validation PMIDs per assay.
KRAS G12C NSCLC. Skoulidis et al. (2021) reported sotorasib in previously treated KRAS G12C-mutant advanced NSCLC (CodeBreaK 100): objective response rate 37.1% (95% CI 28.6% to 46.2%), median PFS 6.8 months.12 KRAS G12C is a genotype-defined treatment gate, not a prognostic correlate alone.
NTRK fusions (tumor-agnostic). Drilon et al. (2018) reported larotrectinib across TRK fusion-positive cancers: ORR 75% (95% CI 61% to 85%) in 55 patients spanning 17 tumor types.13 Rare fusion prevalence means histology-specific subgroups are small; read confidence intervals, not headline ORR alone.
Tumor Mutational Burden as an Immunotherapy Biomarker
Samstein et al. (2019) analyzed 1,662 advanced cancer patients treated with immune checkpoint inhibitors whose tumors underwent MSK-IMPACT sequencing. Higher somatic TMB (top 20% within each histology) associated with better overall survival (HR 0.52 versus bottom 80%).15 TMB cutpoints that correlated with benefit varied markedly between cancer types. There is no single universal "high TMB" threshold across histologies.
Read our blog on immunotherapy biomarkers for PD-L1, TMB, and MSI evidence boundaries and our blog on patient stratification for enrichment trial design.
NGS Panels and Actionability
Tumor profiling panels differ in gene content, LOD, and reporting rules. Zehir et al. (2017) demonstrate that "actionable" yield is a function of panel design and therapy availability, not genomics alone.14 Before ordering broad NGS, teams should map which alteration-drug pairs have pivotal evidence in the patient's line of therapy.
Literature review questions for each reported alteration:
- Was benefit shown in first-line, adjuvant, or post-progression settings?
- Which assay and cutoff defined positivity in pivotal trials?
- Is the alteration a companion diagnostic for a specific FDA-approved therapy?
- Do resistance papers list mechanisms relevant at progression?
Variants of Uncertain Significance and Plasma-Tissue Discordance
NGS panels routinely return variants of uncertain significance (VUS). A VUS is not an actionable biomarker until functional or segregation evidence upgrades classification (Richards et al., 2015).16 Tumor boards that treat VUS as therapeutic targets without literature support for that variant-drug pair violate predictive biomarker logic.
Plasma genotyping concordance with tissue is indication- and variant-dependent. Paweletz et al. (2015) showed plasma EGFR mutation detection can identify T790M at progression when tissue re-biopsy fails, but sensitivity varies by allele fraction and assay LOD.17 Liquid biopsy complements tissue; it does not universally replace it for initial diagnosis unless the intended-use label and validation PMIDs support plasma-first pathways.
Read our blog on liquid biopsy biomarkers for ctDNA assay architecture and CHIP interpretation.
Resistance Mechanisms: Why Serial Genotyping Matters
Targeted therapy selects for resistant clones. Leonetti et al. (2019) review osimertinib resistance in EGFR-mutant NSCLC: EGFR C797S, MET or HER2 amplification, RAS-MAPK or PI3K pathway activation, novel fusions, and histologic transformation.18 Resistance spectra differ between first-line and post-TKI osimertinib.
Liquid biopsy can capture emergent alterations at progression. Read our blog on liquid biopsy biomarkers for ctDNA monitoring evidence.
Companion Diagnostics and Regulatory Context
Companion diagnostics tie assay results to specific therapies and require co-developed analytical and clinical validity evidence. Biomarker qualification for drug development tools differs from CDx product approval (Amur et al., 2011).19 Read our blog on FDA biomarker validation for qualification vs CDx pathways.
Read our blog on personalized medicine biomarker analysis for basket trials and master protocols.
Basket Trials and Tumor-Agnostic Indications
Tumor-agnostic approvals tie therapy to genomic alteration regardless of histology when pivotal evidence supports the pairing. MSI-H/dMMR and NTRK fusions illustrate alteration-driven labels that require centralized assay validation and consistent reporting across sites (Marabelle et al., 2022).
Basket trials enroll multiple tumor types sharing a genomic feature. Literature review must capture histology-specific subgroup sizes; aggregate ORR can hide null subgroups. Simon (2013) warns against treating basket trial aggregates as uniform predictive evidence across all enrolled histologies.3
Read our blog on patient stratification for enrichment design when genomic criteria gate enrollment.
Common Failure Modes in Genomic Biomarker Programs
- Ordering broad NGS panels without a therapy-linked question for each actionable alteration
- Applying TMB cutoffs from one histology to another without indication-specific validation literature
- Treating germline BRCA status as sufficient for PARP benefit without tumor HRD context in some settings
- Ignoring resistance papers when planning serial biopsy or liquid biopsy at progression
- Relabeling prognostic markers as predictive without treatment interaction evidence (Simon, 2013)
- Pooling PMIDs that used different NGS panels, LODs, or variant calling pipelines
Scoping Genomic Evidence in Motif
Before tumor boards or protocol synopses lock inclusion criteria, teams need a cited map of alteration-drug evidence. Motif supports:
- Search for gene-variant-drug associations in your indication and line of therapy
- Extract effect sizes, trial names, and PMIDs with predictive vs prognostic labels
- Cross-reference variants to ClinVar and genes to standard ontologies
- Flag conflicting cohorts and resistance mechanism papers
- Export cited tables for tumor board packets or protocol backgrounds
See biomarker discovery on Motif and cited literature review.
Related Articles
- Immunotherapy biomarkers: PD-L1, TMB, MSI checkpoint evidence
- Liquid biopsy biomarkers: ctDNA at progression and MRD
- Multi-omics integration: combining genomic layers with proteomics and metabolomics
Frequently Asked Questions
What are genomic biomarkers in cancer?
Genomic biomarkers are DNA or RNA alterations (mutations, fusions, expression signatures, MSI status) that inform diagnosis, prognosis, or therapy selection when validated for a specific clinical context (Hoadley et al., 2014; FDA-NIH, 2016).
What is the difference between predictive and prognostic genomic biomarkers?
Predictive biomarkers identify patients more likely to benefit from a specific treatment. Prognostic biomarkers predict outcome regardless of therapy. Enrichment and companion diagnostic claims require predictive evidence with treatment interaction (Simon, 2013; FDA-NIH, 2016).
Which genomic biomarkers have pivotal trial evidence for targeted therapy?
Examples include EGFR mutations for EGFR-TKIs in NSCLC (Mok et al., 2009; Soria et al., 2018), BRAF V600E for BRAF inhibitors in melanoma (Chapman et al., 2011), germline BRCA mutations for PARP inhibitors in breast cancer (Robson et al., 2017), and MSI-H/dMMR for pembrolizumab in defined settings (Marabelle et al., 2022).
Is tumor mutational burden a universal immunotherapy biomarker?
No. Samstein et al. (2019) found TMB associated with checkpoint inhibitor survival but optimal cutpoints varied by cancer type. TMB thresholds from one histology should not be applied to another without indication-specific validation literature.
Why does resistance genotyping matter after targeted therapy?
Targeted agents select resistant clones with distinct mechanisms (Leonetti et al., 2019). Serial tissue or liquid biopsy at progression informs next-line therapy and trial enrollment. Resistance literature should be mapped per drug class and line of therapy.
How should a tumor board treat a VUS on an NGS report?
A variant of uncertain significance is not an actionable biomarker until evidence upgrades its classification (Richards et al., 2015). Literature review should map whether the specific variant has functional data, segregation evidence, or drug-response PMIDs before equating a VUS with a predictive gate for therapy.
How should teams review genomic biomarker literature before NGS orders or trial design?
Map alteration-drug PMIDs by line of therapy, assay platform, and BEST category. Motif extracts cited associations and cross-references variants so tumor boards start from traceable evidence rather than panel report defaults alone.
References
- Hoadley, K.A., et al. (2014). Multiplatform analysis of 12 cancer types. Cell, 158(4), 929-944. PMID: 24120142
- FDA-NIH Biomarker Working Group. (2016). BEST Resource. PMID: 27010052
- Simon, R.M. (2013). Genomic biomarkers in predictive medicine. EMBO Molecular Medicine, 5(6), 813-818. PMID: 23818349
- Mok, T.S., et al. (2009). Gefitinib or chemotherapy for EGFR-mutated NSCLC. NEJM, 361(10), 947-957. PMID: 19692680
- Soria, J.C., et al. (2018). Osimertinib in untreated EGFR-mutated advanced NSCLC. NEJM, 378(2), 113-125. PMID: 29151359
- Ramalingam, S.S., et al. (2020). Overall survival with osimertinib in EGFR-mutated NSCLC. NEJM, 382(1), 41-50. PMID: 31751012
- Chapman, P.B., et al. (2011). Vemurafenib in BRAF V600E melanoma. NEJM, 364(26), 2507-2516. PMID: 21639808
- Robson, M., et al. (2017). Olaparib for metastatic breast cancer with germline BRCA mutation. NEJM, 377(6), 523-533. PMID: 28578601
- Slamon, D.J., et al. (2001). Trastuzumab plus chemotherapy for HER2-positive breast cancer. NEJM, 344(11), 783-792. PMID: 11248153
- Marabelle, A., et al. (2022). Pembrolizumab in MSI-H cancers: KEYNOTE-158. Ann Oncol, 33(10), 1032-1042. PMID: 35680043
- Litton, J.K., et al. (2018). Olaparib tablets in BRCA-mutated advanced ovarian cancer (SOLO-1). New England Journal of Medicine, 379(26), 2495-2505. PMID: 31157963
- Skoulidis, F., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine, 384(25), 2371-2381. PMID: 33413595
- Drilon, A., et al. (2018). Larotrectinib in TRK fusion-positive cancers. New England Journal of Medicine, 378(8), 731-739. PMID: 29466156
- Zehir, A., et al. (2017). MSK-IMPACT clinical sequencing. JCO, 35(18), 2011-2017. PMID: 28481382
- Samstein, R.M., et al. (2019). Tumor mutational load predicts survival after immunotherapy. Nat Genet, 51(2), 202-206. PMID: 30643254
- Richards, S., et al. (2015). ACMG standards for interpretation of sequence variants. Genetics in Medicine, 17(5), 405-424. PMID: 25741868
- Paweletz, C.P., et al. (2015). BEAMing for EGFR T790M in NSCLC. Clinical Cancer Research, 21(24), 5681-5687. PMID: 26230633
- Leonetti, A., et al. (2019). Resistance to osimertinib in EGFR-mutated NSCLC. Br J Cancer, 121(9), 725-737. PMID: 31564718
- Amur, S., et al. (2011). Biomarker qualification framework. Clinical Pharmacology & Therapeutics, 89(3), 393-401. PMID: 21270794
